This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Veterans are entitled to healthcare if they develop conditions related to their service. But too many of them are dying without being helped.

Here, a former spousal caregiver shares her story of Parkinson’s disease intruding on her family ... and as the disease gets ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

What the Trained Eye Cannot See: Detecting Movement Defects in Early Stage Parkinson's Disease Aug. 15, 2024 — Using machine learning to analyze video recordings of individuals performing simple ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

Late in Earl Ross’s life, Parkinson’s disease robbed him of his mobility ... earned induction into seven different Halls of ...

(This column is part of “The Light of Faith and Care at the Sunset of Life,” a series on the Catholic Standard website and ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.